Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
£ 1850
Key Takeaways
Risk factor
Poor trading liquidity
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very strong margins and returns
Data is available to registered users only
Data is available to registered users only
About
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, infectious disease, oncology, and miscellaneous indications. It also provides contract SMAs and recombinant services. Bioventix PLC was incorporated in 2003 and is based in London, the United Kingdom.
Company Valuation
Based on key historical and expected multiples, the stock is slightly undervalued relative to its peers. Specifically, the stock is 'cheap' on P/E, neutral on EV/EBITDA,
Data is available to registered users only
Buy
Sell